Impact of proning with and without inhaled pulmonary vasodilators and neuromuscular blocking agents in COVID acute respiratory distress syndrome

Table 5 Secondary outcomes from day 0 to day 7 after initiation of intervention per treatment subgroup

Intervention	Day	Arterial oxygen partial pressure/fractional inspired oxygen Ratio			Plateau pressure			Compliance			Driving pressure			Oxygen index
		Mean	∆ From day 0	P value	Mean	∆ From day 0	P value	Mean	∆ From day 0	P value	Mean	∆ From day 0	P value	Mean	∆ From day 0	P value
PPV	0	121.6	-	-	23.4	-	-	39.4	-	-	12.0	-	-	13.1	-	-
	1	141.5	16.3	0.00a	24.3	0.9	0.31	39.1	-0.3	0.88	12.7	0.7	0.42	10.4	-2.6	0.04a
	2	150.4	23.7	0.00a	24.0	0.6	0.56	37.8	-1.7	0.55	12.8	0.8	0.43	10.3	-2.7	0.09
	3	139.8	15.0	0.05a	23.9	0.5	0.66	35.2	-4.3	0.16	13.2	1.2	0.30	11.9	-1.1	0.53
	4	142.2	16.9	0.05a	24.3	0.9	0.45	36.2	-3.3	0.30	13.6	1.7	0.16	11.4	-1.7	0.39
	5	142.4	17.1	0.07	24.2	1.8	0.17	35.3	-4.1	0.19	14.5	2.5	0.04a	12.7	-0.3	0.87
	6	140.1	15.2	0.12	24.7	1.2	0.34	35.1	-4.4	0.18	14.9	2.9	0.02a	12.2	-0.8	0.69
	7	140.9	15.9	0.12	24.8	1.4	0.29	35.0	-4.4	0.18	15.1	3.1	0.01a	11.6	-1.1	0.61
PPV and IVd	0	109.3	-	-	25.0	-	-	36.3	-	-	13.6	-	-	11.5	-	-
	1	124.9	14.4	0.01a	26.3	1.2	0.13	38.1	1.8	0.49	13.1	-0.5	-	14.0	2.6	0.05
	2	136.1	24.6	0.00a	26.1	1.1	0.26	38.1	1.8	0.55	12.2	-1.3	0.51	13.4	2	0.22
	3	133.3	22.0	0.01a	26.9	1.9	0.08	34.3	-2	0.52	14.2	0.6	0.18	13.5	2.1	0.25
	4	129.8	18.8	0.03a	27.7	2.6	0.02a	34.2	-2.1	0.51	15.2	1.7	0.55	13.8	2.4	0.22
	5	136.1	24.5	0.01a	27.1	2.0	0.09	36.6	0.3	0.92	15.1	1.6	0.14	13.0	1.6	0.44
	6	134.2	22.8	0.02a	27.8	2.7	0.03a	32.7	-3.6	0.28	16.3	2.8	0.18	13.6	2.2	0.30
	7	138.5	26.8	0.01a	27.4	2.3	0.07	32.5	-3.8	0.26	16.0	2.4	0.02a	12.6	1.2	0.58
PPV and NMBA	0	108.3	-	-	25.9	-	-	35.9	-	-	-	-	-	11.8	-	-
	1	115.6	6.8	0.54	29.7	3.8	0.13	29.2	-6.7	0.33	18.7	2.3	0.40	12.3	0.5	0.86
	2	115.6	6.8	0.65	27.7	1.8	0.54	32.3	-3.7	0.66	18.3	1.9	0.53	10.2	-1.7	0.65
	3	115.6	6.8	0.70	27.1	1.2	0.71	23.1	-12.8	0.15	18.6	2.2	0.50	12.0	0.2	0.96
	4	119.5	10.3	0.61	26.8	0.9	0.79	34.9	-1.1	0.91	19.4	3	0.38	9.7	-2.2	0.64
	5	120.4	11.3	0.60	24.8	-1.0	0.77	35.8	-0.1	0.99	16.8	0.6	0.86	11.2	-0.6	0.91
	6	130.6	20.6	0.40	24.6	-1.2	0.74	36.4	0.5	0.96	16.8	0.6	0.86	10.2	-1.6	0.75
	7	127.6	17.8	0.47	24.6	-1.2	0.74	36.4	0.5	0.96	17.0	0.8	0.82	11.0	-0.8	0.87
PPV, IVd and NMBA	0	119.5	-	-	25.9	-	-	28.8	-	-	14.7	-	-	14.4	-	-
	1	102.0	-3.0	0.78	27.6	1.7	0.28	36.7	7.9	0.06	14.4	-0.3	0.86	18.0	3.6	0.19
	2	98.6	-6.2	0.64	25.8	-0.1	0.97	40.1	11.3	0.02a	12.9	-1.8	0.32	18.9	4.4	0.19
	3	119.5	-10.9	0.46	26.4	0.6	0.78	38.0	9.2	0.08	13.2	-1.6	0.43	20.5	6	0.11
	4	119.5	23.8	0.21	24.6	-1.3	0.55	35.5	6.6	0.22	12.9	-1.8	0.40	14.7	0.3	0.95
	5	122.7	16.8	0.39	24.4	-1.4	0.52	37.1	8.3	0.13	13.7	-1	0.63	13.4	-1	0.81
	6	123.9	18.0	0.40	25.7	-0.2	0.94	37.4	8.6	0.12	15.0	-0.1	0.96	11.6	-2.8	0.52
	7	127.2	21.1	0.34	23.4	-2.4	0.29	37.7	8.9	0.12	13.0	-2.1	0.34	11.0	-3.5	0.44

^aStatistically significant value (P < 0.05).

IVd: Inhaled vasodilators; NMBA: Neuromuscular blocking agents; PPV: Prone position ventilation.